Eli Lilly (NYSE:LLY) and Amgen (NASDAQ:AMGN) announce a global antibody manufacturing collaboration to increase the supply capacity available for Lilly’s potential COVID-19 therapies.
Through this collaboration, the two companies will have the ability to quickly scale up production and serve more patients if Lilly’s antibody therapies prove successful and receive regulatory approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.